Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, announced today the achievement of the first clinical milestone in its antibody discovery collaboration with Eli Lilly and Company of Indianapolis, Indiana, U.S.A. The milestone, the commencement of patient enrollment for a Phase I study of an antibody discovered under the collaboration agreement, triggers an undisclosed milestone payment to AbCheck from Lilly. Further details about the study and antibody were not disclosed.
“This clinical milestone represents an important validation of our unique combination of technology platforms,” commented Dr. Volker Lang, Managing Director of AbCheck. “We are very pleased our technology has enabled the discovery of another antibody that has advanced to the clinic, demonstrating again that our technology is reliably capable of delivering high-quality antibodies suitable for clinical development.”
Under the collaboration agreement, AbCheck has used its antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, pay AbCheck discovery fees and development milestone payments; other financial and deal terms were not disclosed.
About AbCheck
AbCheck discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies. We use phage/yeast display libraries (AbSieve), mass humanization and antibody optimization (AbAccel) to provide high quality leads. Our technology platform can be used in conjunction with all antibody designs and allows selection of optimized leads from a huge number of variants. Flexibly adapting to our partners’ needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH.
For more information: AbCheck s.r.o. Dr. Volker Lang Managing Director +420 378 051500 [email protected]
